The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...

Scalded skin syndrome from staph bacteria generally covers the entire body. Infants are particularly susceptible. Learn which ...

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 77,700 shares, a ...

(NASDAQ:ARGX – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a report released on Friday,RTT News reports. William Blair also issued estimates for ...

Modern science and the ever-evolving tools of examination have brought about a revolutionary change in how we understand, ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

Mirum Pharma's Ctexli has become the first FDA-approved therapy for cerebrotendinous xanthomatosis (CTX), an ultra-rare form ...

Bullous pemphigoid is an autoimmune skin disease characterized by tense blisters and erosions. In this Primer, Akbarialiabad et al. review the epidemiology, pathophysiology, diagnosis and ...